146 related articles for article (PubMed ID: 37395756)
1. Intensive sampling of the umbra and penumbra improves clinically significant prostate cancer detection and reduces risk of grade group upgrading at radical prostatectomy.
Lee AYM; Chen K; Cheng CWS; Ho HSS; Yuen JSP; Ngo NT; Law YM; Tay KJ
World J Urol; 2023 Aug; 41(8):2265-2271. PubMed ID: 37395756
[TBL] [Abstract][Full Text] [Related]
2. Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling.
Brisbane WG; Priester AM; Ballon J; Kwan L; Delfin MK; Felker ER; Sisk AE; Hu JC; Marks LS
Eur Urol; 2022 Sep; 82(3):303-310. PubMed ID: 35115177
[TBL] [Abstract][Full Text] [Related]
3. The role of perilesional and multiparametric resonance imaging-targeted biopsies to reduce the risk of upgrading at radical prostatectomy pathology: A retrospective monocentric study.
Diamand R; Hollans M; Lefebvre Y; Sirtaine N; Limani K; Hawaux E; Abou Zahr R; Mattlet A; Albisinni S; Roumeguère T; Peltier A
Urol Oncol; 2022 May; 40(5):192.e11-192.e17. PubMed ID: 35236622
[TBL] [Abstract][Full Text] [Related]
4. Pathological findings at radical prostatectomy of biopsy naïve men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling.
Luzzago S; Petralia G; Maresca D; Sabatini I; Cordima G; Brescia A; Verweij F; Garelli G; Mistretta FA; Cioffi A; Pricolo P; Alessi S; Ferro M; Matei DV; Renne G; de Cobelli O; Musi G
Urol Oncol; 2020 Dec; 38(12):929.e11-929.e19. PubMed ID: 32600928
[TBL] [Abstract][Full Text] [Related]
5. Clinically significant prostate cancer (csPCa) detection with various prostate sampling schemes based on different csPCa definitions.
Wang F; Chen T; Wang M; Chen H; Wang C; Liu P; Liu S; Luo J; Ma Q; Xu L
BMC Urol; 2021 Dec; 21(1):183. PubMed ID: 34949183
[TBL] [Abstract][Full Text] [Related]
6. Optimizing Spatial Biopsy Sampling for the Detection of Prostate Cancer.
Raman AG; Sarma KV; Raman SS; Priester AM; Mirak SA; Riskin-Jones HH; Dhinagar N; Speier W; Felker E; Sisk AE; Lu D; Kinnaird A; Reiter RE; Marks LS; Arnold CW
J Urol; 2021 Sep; 206(3):595-603. PubMed ID: 33908801
[TBL] [Abstract][Full Text] [Related]
7. Pathological features of Prostate Imaging Reporting and Data System (PI-RADS) 3 MRI lesions in biopsy and radical prostatectomy specimens.
Rahota RG; Diamand R; Malavaud B; Fiard G; Descotes JL; Peltier A; Beauval JB; Roumeguère T; Roumiguié M; Albisinni S; Ploussard G
BJU Int; 2022 May; 129(5):621-626. PubMed ID: 34358405
[TBL] [Abstract][Full Text] [Related]
8. Optimizing multiparametric magnetic resonance imaging-targeted biopsy and detection of clinically significant prostate cancer: the role of perilesional sampling.
Noujeim JP; Belahsen Y; Lefebvre Y; Lemort M; Deforche M; Sirtaine N; Martin R; Roumeguère T; Peltier A; Diamand R
Prostate Cancer Prostatic Dis; 2023 Sep; 26(3):575-580. PubMed ID: 36509930
[TBL] [Abstract][Full Text] [Related]
9. Can fewer transperineal systematic biopsy cores have the same prostate cancer detection rate as of magnetic resonance imaging/ultrasound fusion biopsy?
Liu H; Ruan M; Wang H; Wang H; Li X; Song G
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):589-595. PubMed ID: 32719353
[TBL] [Abstract][Full Text] [Related]
10. Role of targeted biopsy, perilesional biopsy, and random biopsy in prostate cancer diagnosis by mpMRI/transrectal ultrasonography fusion biopsy.
Novara G; Zattoni F; Zecchini G; Aceti A; Pellizzari A; Ferraioli G; Carlesso M; La Bombarda G; Morlacco A; Lacognata CS; Lauro A; Gardiman M; Betto G; Zanovello N; Moro FD
World J Urol; 2023 Nov; 41(11):3239-3247. PubMed ID: 37079076
[TBL] [Abstract][Full Text] [Related]
11. Current role of systematic biopsy in diagnosis of clinically significant prostate cancer in primary combined MRI-targeted biopsy: a high-volume single-center study.
Krausewitz P; Fostitsch D; Weiten R; Kluemper N; Stein J; Luetkens J; Kristiansen G; Ellinger J; Ritter M
World J Urol; 2023 Jan; 41(1):19-25. PubMed ID: 36477403
[TBL] [Abstract][Full Text] [Related]
12. Novel sampling scheme with reduced cores in men with multiparametric MRI-visible lesions undergoing prostate biopsy.
Ruan M; Wang H; Li X; Song G
Abdom Radiol (NY); 2023 Jun; 48(6):2139-2147. PubMed ID: 37036488
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic Yield of Incremental Biopsy Cores and Second Lesion Sampling for In-Gantry MRI-Guided Prostate Biopsy.
Seyfried N; Mahran A; Panda A; Obmann VC; Buzzy CA; Jiang Y; Wright KL; Nakamoto DA; Patel IJ; Conroy B; Ponsky L; Gulani V
AJR Am J Roentgenol; 2021 Oct; 217(4):908-918. PubMed ID: 33336582
[No Abstract] [Full Text] [Related]
14. A multicentric study on accurate grading of prostate cancer with systematic and MRI/US fusion targeted biopsies: comparison with final histopathology after radical prostatectomy.
Diamand R; Oderda M; Al Hajj Obeid W; Albisinni S; Van Velthoven R; Fasolis G; Simone G; Ferriero M; Roche JB; Piechaud T; Pastore A; Carbone A; Fiard G; Descotes JL; Marra G; Gontero P; Altobelli E; Papalia R; Kumar P; Eldred-Evans D; Giacobbe A; Muto G; Lacetera V; Beatrici V; Roumeguere T; Peltier A
World J Urol; 2019 Oct; 37(10):2109-2117. PubMed ID: 30652213
[TBL] [Abstract][Full Text] [Related]
15. Gleason Grade Group Concordance between Systematic Template Combining Magnetic Resonance Imaging Fusion Targeted Biopsy and Radical Prostatectomy Specimens: A Comparison of Transperineal and Transrectal Approaches.
Wu S; Feldman AS; Kim MM; Lin SX; Cornejo KM; Harisinghani MG; Dahl DM; Wu CL
Urology; 2023 May; 175():151-156. PubMed ID: 36828261
[TBL] [Abstract][Full Text] [Related]
16. Risk of Upgrading from Prostate Biopsy to Radical Prostatectomy Pathology-Does Saturation Biopsy of Index Lesion during Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy Help?
Calio BP; Sidana A; Sugano D; Gaur S; Maruf M; Jain AL; Merino MJ; Choyke PL; Wood BJ; Pinto PA; Turkbey B
J Urol; 2018 Apr; 199(4):976-982. PubMed ID: 29154904
[TBL] [Abstract][Full Text] [Related]
17. MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naïve patients: follow-up of a PRECISION trial-like retrospective cohort.
Luzzago S; de Cobelli O; Mistretta FA; Piccinelli ML; Lorusso V; Morelli M; Bianchi R; Catellani M; Cozzi G; Di Trapani E; Pricolo P; Alessi S; Ferro M; Marvaso G; Matei DV; Jereczek-Fossa BA; Petralia G; Musi G
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):406-413. PubMed ID: 32989259
[TBL] [Abstract][Full Text] [Related]
18. A Prospective Comparison of Transrectal Standard, Cognitive, Transperineal Fusion, and Mapping Prostate Biopsy for Cancer Detection.
Petov V; Bazarkin A; Morozov A; Taratkin M; Ganzha T; Danilov S; Chernov Y; Chinenov D; Rzayev R; Suvorov A; Amosov A; Fajkovic H; Enikeev D; Krupinov G
J Endourol; 2023 Aug; 37(8):940-947. PubMed ID: 37294206
[No Abstract] [Full Text] [Related]
19. Performance of systematic, MRI-targeted biopsies alone or in combination for the prediction of unfavourable disease in MRI-positive low-risk prostate cancer patients eligible for active surveillance.
Ploussard G; Beauval JB; Lesourd M; Almeras C; Assoun J; Aziza R; Gautier JR; Loison G; Portalez D; Salin A; Tollon C; Soulié M; Malavaud B; Roumiguié M
World J Urol; 2020 Mar; 38(3):663-671. PubMed ID: 31197523
[TBL] [Abstract][Full Text] [Related]
20. Optimized grade group for reporting prostate cancer grade in systematic and MRI-targeted biopsies.
He Y; Shen Q; Fu W; Wang H; Song G
Prostate; 2022 Aug; 82(11):1125-1132. PubMed ID: 35538399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
